WO1986003206A1 - Esters d'hydrates de carbone d'acide acetylsalicylique, procede pour leur preparation et compositions pharmaceutiques - Google Patents
Esters d'hydrates de carbone d'acide acetylsalicylique, procede pour leur preparation et compositions pharmaceutiques Download PDFInfo
- Publication number
- WO1986003206A1 WO1986003206A1 PCT/AT1985/000050 AT8500050W WO8603206A1 WO 1986003206 A1 WO1986003206 A1 WO 1986003206A1 AT 8500050 W AT8500050 W AT 8500050W WO 8603206 A1 WO8603206 A1 WO 8603206A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acetylsalicylic acid
- acetylsalicyloyl
- water
- glucose
- mono
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 14
- 238000002360 preparation method Methods 0.000 title claims description 7
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical class [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 title abstract 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 title description 6
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 23
- 239000007924 injection Substances 0.000 claims abstract description 4
- 238000002347 injection Methods 0.000 claims abstract description 4
- -1 acetylsalicyloyl Chemical group 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 19
- 235000014633 carbohydrates Nutrition 0.000 claims description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 17
- 239000008103 glucose Substances 0.000 claims description 15
- 150000002772 monosaccharides Chemical class 0.000 claims description 15
- DSGKWFGEUBCEIE-UHFFFAOYSA-N (2-carbonochloridoylphenyl) acetate Chemical compound CC(=O)OC1=CC=CC=C1C(Cl)=O DSGKWFGEUBCEIE-UHFFFAOYSA-N 0.000 claims description 10
- 150000001720 carbohydrates Chemical class 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 125000006239 protecting group Chemical group 0.000 claims description 10
- 239000005720 sucrose Substances 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 150000002016 disaccharides Chemical class 0.000 claims description 8
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 150000001719 carbohydrate derivatives Chemical class 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 4
- 238000001228 spectrum Methods 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 229960001031 glucose Drugs 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 229960003082 galactose Drugs 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229940077731 carbohydrate nutrients Drugs 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000032050 esterification Effects 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- 229960002737 fructose Drugs 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 0 CS(C)(CC1)C*1C1=CCCCC1*=O Chemical compound CS(C)(CC1)C*1C1=CCCCC1*=O 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 238000003436 Schotten-Baumann reaction Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- LLZWORYYLBQNJZ-UHFFFAOYSA-N 2-acetyloxy-3-ethylbenzoic acid Chemical compound CCC1=CC=CC(C(O)=O)=C1OC(C)=O LLZWORYYLBQNJZ-UHFFFAOYSA-N 0.000 description 1
- DVIHKVWYFXLBEM-UHFFFAOYSA-N 2-hydroxybenzoyl chloride Chemical compound OC1=CC=CC=C1C(Cl)=O DVIHKVWYFXLBEM-UHFFFAOYSA-N 0.000 description 1
- HNNSIJBHYRILKJ-UHFFFAOYSA-N 6-oxocyclohexa-2,4-diene-1-carboxylic acid Chemical class OC(=O)C1C=CC=CC1=O HNNSIJBHYRILKJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ZBDWZEKORJXOFI-UHFFFAOYSA-N C(C)=C1C(CCCC1)=C1C(C(=CC=C1)B(O)O)=CC1=CC=CC=C1 Chemical compound C(C)=C1C(CCCC1)=C1C(C(=CC=C1)B(O)O)=CC1=CC=CC=C1 ZBDWZEKORJXOFI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- ZVARSKBWVMXPQO-UHFFFAOYSA-N [2-(chloromethyl)phenyl] acetate Chemical compound CC(=O)OC1=CC=CC=C1CCl ZVARSKBWVMXPQO-UHFFFAOYSA-N 0.000 description 1
- 229940068372 acetyl salicylate Drugs 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940041290 mannose Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000002771 monosaccharide derivatives Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940083465 painzone Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- ZSHCCKMFNUELAM-QTCIEIIFSA-N phenyl-[(2r,3r,4s,5s,6r)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)oxan-2-yl]methanone Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@]1(O)C(=O)C1=CC=CC=C1 ZSHCCKMFNUELAM-QTCIEIIFSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
Definitions
- Carbohydrate esters of acetylsalicylic acid process for their preparation and pharmaceutical compositions
- the invention relates to new, analgesic and anti-rheumatic carbohydrate esters of acetylsalicylic acid, which are characterized by a broader therapeutic spectrum compared to acetylsalicylic acid and by good water solubility, a process for their preparation and pharmaceutical compositions containing the new esters.
- Acetylsalicylic acid - best known under the trade name Aspirin - is a drug that has been known for over 100 years and has been successfully used to treat pain, fever, acute or chronic inflammation and as an aggregation inhibitor for platelets. Both the mechanism of action, the pharmacokinetics, the metabolism and the side effects of acetylsalicylic acid have meanwhile been examined very carefully, see for example A. Hawkins et al., Science 160 (1968) 780; H. Klotz u. G. Tarn, Proc. Nat. Acad. Sci. USA 70 (1973) 1313; C. Fereira et al., Nature 240 (1972) 340; D. Willis, Science 183 (1974) 325; E. hackenthal, Austrian. maschinerZeitung 36 (1982) 837.
- acetylsalicylic acid Because of its poor solubility in water (approx. 1 g / 100 ml water at 37 ° C), acetylsalicylic acid has so far only been administered orally. For various therapeutic purposes, in particular when high doses are indicated, for example in the treatment of rheumatic diseases, it can therefore not be used or can only be used with insufficient action, since sufficient amounts of active ingredient cannot be obtained at the actual site of action. In addition, the oral application of the often required high doses also causes gastrointestinal symptoms, such as bleeding or other undesirable side effects, see L. Hussey et al, J. Am.Med.Ass. 228 (1974) 609.
- No. 4,242,330 which relates to a very special, therapeutically useful derivative of acetylsalicylic acid, namely the compound 1-0- (2-acetoxy) benzoyl- ⁇ -D-2-deoxy / glucopyranose, is also used another carbohydrate ester derivative of acetylsalicylic acid, namely the compound 1-0- (2'-acetoxy) benzoyl- ⁇ -D-glucopyranose.
- the latter compound tends to form the corresponding sugar derivative of salicylic acid instead of the therapeutically active acetylsalicylic acid during hydrolysis. If hydrolysis to acetylsalicylic acid takes place at all, this is extremely slow and to an extent insufficient for therapeutic use.
- O-esters of monosaccharides are also known which, in addition to at least one ester substitution derived from a salicylic acid, have at least one further ether substitution.
- Such at least doubly substituted monosaccharides are insoluble in water and are not suitable for releasing acetylsalicylic acid.
- DE-PS 264654 describes a process for the preparation of compounds of the sugar types with the monooxybenzoic acids and their carboalkyloxy, acetyl and alkyl derivatives, the aim being as completely esterified sugar derivatives as possible.
- dextrose is reacted with a very large excess of acetylsalicylic acid chloride, a highly substituted acetylsalicyloyl glucose is obtained which is almost insoluble in water.
- the object of the present invention was to develop new, readily water-soluble, neutral and compatible acetylsalicylic acid derivatives with a comparable or improved spectrum of action to acetylsalicylic acid, which can be used not only orally but also according to known injection methods.
- the invention relates to new, water-soluble carbohydrate derivatives with ester-like acetylsalicylic acid residues of the general formula (I)
- Acetylsalicylic acid residue is not esterified with the 1-OH group.
- the new acetylsalicylic acid derivatives of the general formula (I) are water-soluble carbohydrate esters of acetylsalicylic acid, namely pure monoesters with monosaccharides or at most diesters with disaccharides.
- the acetylsalicylic acid esters of monosaccharides are thus pure monoesters, especially since diesters such as glucose - already have a significantly reduced solubility in water.
- monoacetylsalicylic acid esters of monosaccharides are obtained according to the invention by esterification of monosaccharides, the hydroxyl groups of which are partially blocked by known protective groups, for example isopropylene groups, with acetylsalicylic acid or its derivatives, preferably acetylsalicylic acid halides or esters, and subsequent selective elimination of the protective groups.
- protective groups for example isopropylidene group already mentioned, other protective groups for monosaccharides are known from carbohydrate chemistry. Groups suitable, for example ethylidene, cyclohexylidene, benzylidene, phenylboronic acid or trimethylsilyl groups.
- Protected or unsung are used as starting materials for the esterification with acetylsalicylic acid or its derivatives protected monosaccharides, for example pentoses or hexoses such as xylose, arabinose, glucose, galactose, mannose, fructose or their glycosides with mono- or polyhydric alcohols.
- Monosaccharides for example pentoses or hexoses such as xylose, arabinose, glucose, galactose, mannose, fructose or their glycosides with mono- or polyhydric alcohols.
- Disaccharides such as sucrose, maltose, cellobiose, lactose are preferably esterified without protective groups.
- the esterification can in principle be carried out in solvents which simultaneously act as acid scavengers (e.g. pyridine, triethylamine) or in other inert solvents (THF, dioxane, aliphatic or aromatic hydrocarbons, DMF, DMA) with the addition of an acid scavenger.
- acid scavengers e.g. pyridine, triethylamine
- THF dioxane
- aliphatic or aromatic hydrocarbons e.g. aliphatic or aromatic hydrocarbons, DMF, DMA
- the unprotected or protected by isopropylidene groups is presented in 10-20% solution * in pyridine, the acetylsalicylic acid halide, for example acetylsalicylic acid chloride, is added dropwise with stirring at 0-5 ° C. and then stirred for a further 15-20 hours at room temperature .
- the excess solvent is distilled off and the residue is stirred with aqueous sodium bicarbonate solution. After the water has been distilled off, the residue is dissolved in an organic solvent, e.g. B.
- the insoluble salts are filtered off and - in the case of the unprotected carbohydrates - the end product is obtained by distilling off the solvent and vacuum drying.
- the intermediate can be isolated by distilling off the solvent and then split up, or the solution can be used directly for the selective removal of the protective groups.
- the unprotected carbohydrate is preferably dissolved in water and the acetylsalicylic acid derivative is added dropwise with stirring, the pH being kept weakly alkaline at the same time by adding dilute alkali metal hydroxide solution.
- the water is then distilled off in vacuo, the residue is taken up in an organic solvent, and the end product is obtained by filtering off the insoluble salts by distilling off the solvent and vacuum drying. If, instead of the carbohydrates, their protected derivatives are used in this reaction, the product obtained after working up must be subjected to acidic hydrolysis to remove the protective groups.
- Halogenated hydrocarbons diethyl ether or petroleum ether, in which the carbohydrate esters of acetylsalicylic acid are soluble, are suitable for this purpose.
- carboxylic acid esters for example methyl or ethyl acetylsalicylic acid
- suitable organic solvents can be used as the reaction medium for the transesterification, which allow problem-free removal of the alcohol formed (for example methanol or ethanol) from the equilibrium by distillation, for example higher alcohols, dioxane, dimethylformamide, dimethylacetamide.
- the free acetylsalicylic acid itself can also be used in the reaction with the carbohydrates.
- a conventional condensing agent e.g. Dicyclohexylcarbodiimide, required.
- the protective groups can be split off in all cases by known methods using dilute acids, acidic ion exchangers or weakly acidic catalysts.
- the new carbohydrate esters of acetylsalicylic acid obtained according to the invention are solid substances which dissolve up to 40% in water or physiological aqueous saline solutions, resulting in stable solutions which can be applied by known injection methods and which show excellent antipyretic, antiphlogistic, antirheumatic and analgesic effects. This is due to the fact that sufficient amounts of active ingredient can be brought into the immediate vicinity of the pain zone without detour and without undesirable side effects.
- the carbohydrate esters of acetylsalicylic acid according to the invention can also be administered orally both in substance and in solution.
- sucrose 34.2 g (0.1 mol) of sucrose are dissolved in 600 ml of anhydrous pyridine and at 0 to 5 ° C., 6.6 g (0.033 mol) of acetylsalicylic acid chloride are added dropwise with stirring. The mixture is then warmed to room temperature and stirred for a further 20 hours. The solvent is distilled off on a rotary evaporator and the residue is stirred with saturated NaHCO 3 solution. The water is distilled off on a rotary evaporator and the residue is stirred with about 200 ml of isopropanol.
- sucrose 34.2 g (0.1 mol) of sucrose are dissolved in 70 ml of water. Then 6.6 g (0.033 mol) of acetylsalicyl chloride are added dropwise at 0 to 5 ° C. while stirring, the pH being kept at 8 to 9 by the simultaneous addition of 20% sodium hydroxide solution. Then the water is distilled off on a rotary evaporator and the residue is stirred with about 200 ml of isopropanol. The insoluble matters are filtered off, the isopropanol is distilled off on a rotary evaporator and the residue is dried in vacuo at 60 ° C.
- the solvent is distilled off on a rotary evaporator and the residue is taken up in chloroform.
- the solution is washed with water, 1N H 2 SO 4 , 1N NaHCO 3 and water, dried with sodium sulfate and the chloroform is distilled off on a rotary evaporator.
- the residue is dried in vacuo at 60 ° C.
- the solution is washed with water, 1N H 2 SO 4 , 1N NaHCO 3 and water, dried with sodium sulfate and the chloroform is distilled off on a rotary evaporator. The residue is dried in vacuo at 60 ° C.
- the solvent is distilled off on a rotary evaporator and the residue is taken up in chloroform.
- the solution is washed with water, 1N H 2 SO 4 , 1N NaHCO 3 and water, dried with sodium sulfate and the chloroform is distilled off on a rotary evaporator.
- the residue is dried in vacuo at 60 ° C.
- the solution is washed with water, 1N H 2 SO 4 , 1N NaHCO 3 and water, dried with sodium sulfate and the chloroform is distilled off on a rotary evaporator. The residue is dried in vacuo at 60 ° C.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Des dérivés d'hydrates de carbone hydrosolubles avec des restes d'acide acétylsalicylique liés à la manière d'esters présentent un spectre d'activité analogue à celui de l'acide acétylsalicylique et peuvent être administrés aussi bien oralement qu'en particulier par injection.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ATA3775/84 | 1984-11-28 | ||
AT0377584A AT382624B (de) | 1984-11-28 | 1984-11-28 | Verfahren zur herstellung von neuen kohlenhydrat-estern der acetylsalicylsaeure |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1986003206A1 true WO1986003206A1 (fr) | 1986-06-05 |
Family
ID=3555257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AT1985/000050 WO1986003206A1 (fr) | 1984-11-28 | 1985-11-27 | Esters d'hydrates de carbone d'acide acetylsalicylique, procede pour leur preparation et compositions pharmaceutiques |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0202305A1 (fr) |
AT (1) | AT382624B (fr) |
WO (1) | WO1986003206A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998017673A1 (fr) * | 1996-10-21 | 1998-04-30 | Cal International Limited | Esters d'aspirinate d'isosorbide |
US9012411B2 (en) | 2009-12-31 | 2015-04-21 | Organomed Corporation | Formulations from derivatives of curcumin, paclitaxel, and aspirin |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9901858D0 (en) * | 1999-01-29 | 1999-03-17 | Secr Defence | Optical filters |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE264654C (fr) * | ||||
FR1453M (fr) * | 1961-10-09 | 1962-08-20 | Pierre Louis | Médicament analgéique, antithermique, antirhumatismal. |
US3279990A (en) * | 1963-01-31 | 1966-10-18 | Jacobs Albert L | Carbohydrate esters of salicylic acid, their production and administration |
US4241055A (en) * | 1979-05-30 | 1980-12-23 | The University Of Kentucky Research Foundation | Derivatives of aspirin |
US4242330A (en) * | 1979-05-30 | 1980-12-30 | The University Of Kentucky Research Foundation | Derivative of aspirin |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH535757A (de) * | 1969-07-03 | 1973-04-15 | Ciba Geigy Ag | Verfahren zur Herstellung von Hexafuranoseverbindungen |
-
1984
- 1984-11-28 AT AT0377584A patent/AT382624B/de not_active IP Right Cessation
-
1985
- 1985-11-27 WO PCT/AT1985/000050 patent/WO1986003206A1/fr unknown
- 1985-11-27 EP EP19850906023 patent/EP0202305A1/fr not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE264654C (fr) * | ||||
FR1453M (fr) * | 1961-10-09 | 1962-08-20 | Pierre Louis | Médicament analgéique, antithermique, antirhumatismal. |
US3279990A (en) * | 1963-01-31 | 1966-10-18 | Jacobs Albert L | Carbohydrate esters of salicylic acid, their production and administration |
US4241055A (en) * | 1979-05-30 | 1980-12-23 | The University Of Kentucky Research Foundation | Derivatives of aspirin |
US4242330A (en) * | 1979-05-30 | 1980-12-30 | The University Of Kentucky Research Foundation | Derivative of aspirin |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998017673A1 (fr) * | 1996-10-21 | 1998-04-30 | Cal International Limited | Esters d'aspirinate d'isosorbide |
US9012411B2 (en) | 2009-12-31 | 2015-04-21 | Organomed Corporation | Formulations from derivatives of curcumin, paclitaxel, and aspirin |
US20150250844A1 (en) * | 2009-12-31 | 2015-09-10 | James N. Jacob | Formulations from natural products, turmeric, paclitaxel, and aspirin |
Also Published As
Publication number | Publication date |
---|---|
EP0202305A1 (fr) | 1986-11-26 |
ATA377584A (de) | 1986-08-15 |
AT382624B (de) | 1987-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60106489T2 (de) | Zuckersubstituierte 2-azetidinone verwendbar als hypocholesterdenische arzneimittel | |
DE69227588T2 (de) | Verfahren zur Herstellung von Morphin-6-Glucoronide oder substituierte Morphin-6-Glucoronide | |
DE2510866C3 (de) | 4'-epi-Adriamycin a - und ß -Anomer, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
DE2953878C2 (de) | Verfahren zur Herstellung von durch Schutzgruppen N-acylierten Aminoglycosiden | |
WO1986002076A1 (fr) | Derives d'hydrates de carbone tensioactif et procede pour leur preparation | |
DE3347522A1 (de) | N-glycosylierte carbonsaeureamid-derivate als mittel bei der bekaempfung von erkrankungen des rheumatischen formenkreises | |
DE2555479A1 (de) | Verfahren zur herstellung von 3', 4'-alpha-epoxyneamin und verwandten aminoglykosidischen antibiotika sowie die so hergestellten verbindungen | |
DE69602834T2 (de) | Verfahren zur herstellung von anthracyclin antibiotica | |
DE2030402B2 (de) | 3 alpha-Hydroxy-21-hydroxy-5 alphapregnan-11,20-dion-21-ester und Verfahren zu ihrer Herstellung | |
DE2804099A1 (de) | Carminomycinderivate, verfahren zu ihrer herstellung und ihre verwendung | |
WO1986003206A1 (fr) | Esters d'hydrates de carbone d'acide acetylsalicylique, procede pour leur preparation et compositions pharmaceutiques | |
DE3881862T2 (de) | Disaccharidderivate. | |
DE2735455C3 (de) | Daunomycinanaloga, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
DE3739098A1 (de) | Neue substituierte dicarbonsaeure-bis(3,5-dicarbamoyl-2,4,6- trijod-anilide), verfahren zu deren herstellung sowie diese enthaltende roentgenkontrastmittel | |
DE69509377T2 (de) | Anthracyclin-derivate, die ein trifluormethylierte zuckereinheiten enthalten | |
DE2942818C2 (de) | 4'-C-Methyl-4'-O-methyl-daunorubicin und -doxorubicin und deren 4'-Epimere sowie diese Verbindungen enthaltende pharmazeutische Zusammensetzungen | |
DE2924659A1 (de) | Pseudotrisaccharide, ihre herstellung und verwendung als arzneimittel | |
DE2366288B2 (de) | Verfahren zur Herstellung von 3' -Desoxykanamycin B und 3' -Desoxyneamin | |
DE69727680T2 (de) | Stereospezifische Mannosylierung mit hoher Ausbeute | |
AT388166B (de) | Verfahren zur herstellung von neuen wasserloeslichen kohlenhydrat-derivaten | |
DE3317702C2 (fr) | ||
DE3040611A1 (de) | Verfahren zur herstellung von tobramycin | |
DE3116127C2 (de) | Verfahren zur Herstellung von 3'-Desoxykanamycin A | |
DE1793462A1 (de) | N-Aryl-anthranylsaeureester mit monosubstituierten gem-Diolen und Verfahren zu ihrer Herstellung | |
DE3308408C2 (de) | 3"-Desoxystreptomycin, Verfahren zu dessen Herstellung und diese Verbindung enthaltende antibakterielle Zusammensetzungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |